ArticleFrontiers in medicine2025
Effect of esketamine on postoperative pain relief and depressive status in patients with traumatic fractures.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of Esketamine as an Adjuvant for Fascia Iliaca Compartment Block on Postoperative Analgesia in Elderly Patients Undergoing Total Hip Arthroplasty.Pakistan journal of medical sciences · 2026Article
- Perioperative Ketamine and Esketamine for Postoperative Mood Symptoms After Orthopaedic Surgery: A Systematic Review of Randomized Controlled Trials.The archives of bone and joint surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effects of different doses of esketamine combined with sufentanil on postoperative pain relief and depressive states in patients with traumatic fractures. Methods: This prospective, randomized, triple-blind, placebo-controlled trial (registered at the Chinese Clinical Trial Registry, Identifier: ChiCTR2100054238) enrolled 225 patients with traumatic lower limb fractures (ASA I-III, aged 18-64) at Jiangxi Provincial People's Hospital between September 2021 and June 2024. Patients were randomly allocated to three groups ( Results: Both esketamine groups (L and H) demonstrated significantly lower HAMD scores on postoperative days 1 and 3 compared to group C (all Conclusion: Continuous postoperative infusion of esketamine (0.5-0.75 mg/kg over 24 h) in patients with traumatic lower limb fractures effectively alleviates postoperative depressive symptoms, provides opioid-sparing analgesia, reduces opioid-related adverse effects like nausea and vomiting, and is associated with increased BDNF and decreased IL-6 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.